Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2007

View Archived Issues

Enzyme inhibitors identified at Schering-Plough with potential in inflammatory disorders

New anticancer agents claimed by several research groups

GlaxoSmithKline reports second quarter 2007 results

Prx2: a novel therapeutic target in Parkinson's disease

Cell Therapeutics to acquire Zevalin from Biogen Idec for U.S. sales and marketing

DelSite begins toxicology studies of GelVac nasal powder H5N1 vaccine

Neopharm provides pipeline update

Positive results for Novo Nordisk's phase III studies of liraglutide

FDA approvable letter issued for Indevus' drug candidate Valstar

Phase III trial reveals phenylalanine reductions with sapropterin

Sinovac prepares to move its H5N1 vaccine into phase II trials

DNA vaccine shows promise in multiple sclerosis

Phenoxodiol may reduce cisplatin-induced neuropathy

Spectrum Pharmaceuticals reports second quarter 2007 results

FDA grants Tikvah Therapeutics' sodium phenylbutyrate orphan drug status

FDA issues approvable letter to Solvay for drug candidate Creon

Intercell reports interim data from phase II trial of HCV vaccine IC-41

Recent Merck patent claims compounds for the treatment of urinary incontinence

Design and pharmacological characterization of ILS-920 presented at ACS meeting

Macrogenics starts phase I trial of West Nile virus neutralizing antibody

Daiichi Sankyo selects DT-831j as clinical candidate for thrombosis

Thymoglobulin to be studied in new onset type 1 diabetes

Lexicon pursues compounds able to reduce peripheral 5-HT levels as an approach to IBS

Novel PPARalpha/gamma agonists improve blood glucose and lipid profiles in animals

Clinical candidate NYP Y5 antagonist discovered at Banyu

BMS designs dual PPARalpha/gamma activators for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...